ClinicalTrials.gg

TargetBeta

SCN10A

sodium voltage-gated channel alpha subunit 10 · also Nav1.8, hPN3, SNS, PN3 · Sodium voltage-gated channel alpha subunits

13 programs in company-led studies act on SCN10A, from 12 companies: 4 in phase 3, 8 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (11 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
LidocaineruleKeenova Therapeuticsphase 4632 runningSCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
RiluzoleruleSanofiphase 462 runningSCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
CarbamazepineruleGRIN Therapeuticsphase 4211 runningSCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
chloroprocaineruleSinteticaphase 481 runningSCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
CarticaineruleLaboratoires Theaphase 411 runningSCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
LamotrigineruleGlaxoSmithKlinephase 4610 runningSCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
DronedaroneruleSanofiphase 4180 runningCACNA1C, CACNA1D, CACNA1F, CACNA1S, HCN4, KCNJ2, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
PrilocaineruleHaisco Pharmaceutical Groupphase 420 runningSCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
RopivacainerulePainReformphase 3174 runningSCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
HRS-2129Jiangsu HengRui Medicinephase 372 running–the company's pipeline
PhenytoinruleViatrisphase 3101 runningSCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
rufinamideruleEisaiphase 370 runningSCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
LY4515100Eli Lillyphase 233 running–the company's pipeline

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.